Evidence map›Paper›PMID 29192516›Full record

ArticleExperimental biology and medicine (Maywood, N.J.)2018

Knockdown of angiopoietin-like 2 mimics the benefits of intermittent fasting on insulin responsiveness and weight loss.

Cécile Martel, Anthony Pinçon, Alexandre Maxime Bélanger, Xiaoyan Luo, Marc-Antoine Gillis, Olivia de Montgolfier, Nathalie Thorin-Trescases, Éric Thorin

Open access · bronzeAbstract read
In one paragraph

Article in Experimental biology and medicine (Maywood, N.J.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Cécile Martel1 Montreal Heart Institute, Research Center, 12368 University of Montreal , Montreal, QC H1T 1C8, Canada.
Anthony Pinçon1 Montreal Heart Institute, Research Center, 12368 University of Montreal , Montreal, QC H1T 1C8, Canada.
Alexandre Maxime Bélanger1 Montreal Heart Institute, Research Center, 12368 University of Montreal , Montreal, QC H1T 1C8, Canada.
Xiaoyan Luo1 Montreal Heart Institute, Research Center, 12368 University of Montreal , Montreal, QC H1T 1C8, Canada.
Marc-Antoine Gillis1 Montreal Heart Institute, Research Center, 12368 University of Montreal , Montreal, QC H1T 1C8, Canada.
Olivia de Montgolfier2 Departments of Surgery and Pharmacology, Faculty of Medicine, 12368 University of Montreal , Montréal H3T 1J4, QC, Canada.
Nathalie Thorin-Trescases1 Montreal Heart Institute, Research Center, 12368 University of Montreal , Montreal, QC H1T 1C8, Canada.
Éric Thorin1 Montreal Heart Institute, Research Center, 12368 University of Montreal , Montreal, QC H1T 1C8, Canada.
Montreal Heart Institute · CAUniversité de Montréal · CA

Funding

CIHR 133649CIHR 14496
6 · The paper itself

Abstract

Angiopoietin-like 2 (ANGPTL2) is an inflammatory adipokine linking obesity to insulin resistance. Intermittent fasting, on the other hand, is a lifestyle intervention able to prevent obesity and diabetes but difficult to implement and maintain. Our objectives were to characterize a link between ANGPTL2 and intermittent fasting and to investigate whether the knockdown of ANGPTL2 reproduces the benefits of intermittent fasting on weight gain and insulin responsiveness in knockdown and wild-type littermates mice. Intermittent fasting, access to food ad libitum once every other day, was initiated at the age of three months and maintained for four months. Intermittent fasting decreased by 63% (p < 0.05) gene expression of angptl2 in adipose tissue of wild-type mice. As expected, intermittent fasting improved insulin sensitivity (p < 0.05) and limited weight gain (p < 0.05) in wild-type mice. Knockdown mice fed ad libitum, however, were comparable to wild-type mice following the intermittent fasting regimen: insulin sensitivity and weight gain were identical, while intermittent fasting had no additional impact on these parameters in knockdown mice. Energy intake was similar between both wild-type fed intermittent fasting and ANGPTL2 knockdown mice fed ad libitum, suggesting that intermittent fasting and knockdown of ANGPTL2 equally lower feeding efficiency. These results suggest that the reduction of ANGPTL2 could be a useful and promising strategy to prevent obesity and insulin resistance, although further investigation of the mechanisms linking ANGPTL2 and intermittent fasting is warranted. Impact statement Intermittent fasting is an efficient diet pattern to prevent weight gain and improve insulin sensitivity. It is, however, a difficult regimen to follow and compliance is expected to be very low. In this work, we demonstrate that knockdown of ANGPTL2 in mice fed ad libitum mimics the beneficial effects of intermittent fasting on weight gain and insulin sensitivity in wild-type mice. ANGPTL2 is a cytokine positively associated with fat mass in humans, which inactivation in mice improves resistance to a high-fat metabolic challenge. This study provides a novel pathway by which IF acts to limit obesity despite equivalent energy intake. The development of a pharmacological ANGPTL2 antagonist could provide an efficient tool to reduce the burden of obesity.

Indexed as

FastingInsulin ResistanceAngiopoietin-Like Protein 2Angiopoietin-like ProteinsAnimalsGene Knockdown TechniquesHumansHypoglycemic AgentsInsulinMaleMice, Inbred C57BLObesityWeight LossAngiopoietin-Like Protein 2Angiopoietin-like ProteinsAngptl2 protein, mouseHypoglycemic AgentsInsulindiabetesEnergy metabolismmiceobesity

Identifiers

PMID29192516
PMCPMC5788163
OpenAlexW2774231474

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.